Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 15/20 | 0.65 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.65 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809851 | 1.00 | AGTR1 (0.65) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2930427 | 0.93 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL28456708 | 0.93 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2930431 | 0.93 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL10109387 | 0.93 | AGTR1 (0.68) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL14573915 | 0.87 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8204220 | 0.87 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8819112 | 0.85 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8818935 | 0.85 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL28459370 | 0.84 | AGTR1 (0.56) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119657-A1 | PHENYLTETRAZOLE COMPOUNDS | DIPHARMA S. P. A. (IT) | 2008-05-22 | — | — | US | disclosed |
| US-7345072-B2 | Phenyltetrazole compounds | DIPHARMA S.P.A. (IT) | 2008-03-18 | — | — | US | disclosed |
| EP-1555260-B1 | Phenyltetrazole compounds | DIPHARMA FRANCIS SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| EP-1555260-A1 | Phenyltetrazole compounds | Dipharma S.p.A. (IT) | 2005-07-20 | — | — | EP | disclosed |
| US-20050119488-A1 | Phenyltetrazole compounds | DIPHARMA S.P.A. (IT) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119488-A1 | Phenyltetrazole compounds | ACE, AGTR2, ACE2 | AGTR1 4/4885LTB4R2 1194/4885ABCB11 1757/4885 |
| US-20080119657-A1 | PHENYLTETRAZOLE COMPOUNDS | ACE, AGTR2, ACE2 | AGTR1 4/4885LTB4R2 1194/4885ABCB11 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.